Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omaveloxolone Drug-Drug Interaction Study
NCT04008186Phase 1Completed
- Sponsor
- Biogen
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of omaveloxolone in Friedreich ataxia (FA) (4 arms), sponsored by Biogen. Primary endpoints: Maximum Concentration at 28 days and Area Under the Curve at 28 days. Started Jun 2019; status: completed.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NCT04008186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04008186.